MX2020011638A - Regimenes de dosificacion para una inhibicion dirigida del factor de crecimiento transformante beta (tgf-beta) en el tratamiento del cancer en sujetos no tratados previamente. - Google Patents

Regimenes de dosificacion para una inhibicion dirigida del factor de crecimiento transformante beta (tgf-beta) en el tratamiento del cancer en sujetos no tratados previamente.

Info

Publication number
MX2020011638A
MX2020011638A MX2020011638A MX2020011638A MX2020011638A MX 2020011638 A MX2020011638 A MX 2020011638A MX 2020011638 A MX2020011638 A MX 2020011638A MX 2020011638 A MX2020011638 A MX 2020011638A MX 2020011638 A MX2020011638 A MX 2020011638A
Authority
MX
Mexico
Prior art keywords
inhibition
treating cancer
treatment naive
dosing regimens
naive subjects
Prior art date
Application number
MX2020011638A
Other languages
English (en)
Spanish (es)
Inventor
Isabelle Dussault
Bawab Samer El
Yulia Vugmeyster
Akash Khandelwal
Laureen Ojalvo
Olaf Christensen
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2020011638A publication Critical patent/MX2020011638A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MX2020011638A 2018-05-15 2019-05-14 Regimenes de dosificacion para una inhibicion dirigida del factor de crecimiento transformante beta (tgf-beta) en el tratamiento del cancer en sujetos no tratados previamente. MX2020011638A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671963P 2018-05-15 2018-05-15
US201962804931P 2019-02-13 2019-02-13
PCT/US2019/032271 WO2019222252A1 (en) 2018-05-15 2019-05-14 Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naive subjects

Publications (1)

Publication Number Publication Date
MX2020011638A true MX2020011638A (es) 2022-02-10

Family

ID=68540945

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011638A MX2020011638A (es) 2018-05-15 2019-05-14 Regimenes de dosificacion para una inhibicion dirigida del factor de crecimiento transformante beta (tgf-beta) en el tratamiento del cancer en sujetos no tratados previamente.

Country Status (12)

Country Link
US (1) US20210061899A1 (enExample)
EP (1) EP3813868A4 (enExample)
JP (1) JP2021523096A (enExample)
KR (1) KR20210009339A (enExample)
CN (1) CN112118858A (enExample)
AU (1) AU2019271065A1 (enExample)
BR (1) BR112020021082A2 (enExample)
CA (1) CA3096844A1 (enExample)
MX (1) MX2020011638A (enExample)
SG (1) SG11202011148VA (enExample)
TW (1) TW202003577A (enExample)
WO (1) WO2019222252A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3158047A1 (en) * 2019-12-11 2021-06-17 Yunying CHEN Bi-functional antibody against pd-l1 and tgf?
WO2021218883A1 (zh) * 2020-04-28 2021-11-04 神州细胞工程有限公司 一种TGFβR2胞外区截短分子、其与抗EGFR抗体的融合蛋白及其抗肿瘤用途
EP4194002A4 (en) * 2020-07-24 2024-08-14 Mabwell (Shanghai) Bioscience Co., Ltd. TGF-BETA RII MUTANT AND ASSOCIATED FUSION PROTEIN

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201216649D0 (en) * 2012-09-18 2012-10-31 Univ Birmingham Agents and methods
MY186864A (en) * 2013-03-12 2021-08-26 Biocon Ltd Fusion immunomodulatory proteins and methods for making same
HRP20210977T1 (hr) * 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
SG10201913538VA (en) * 2015-11-23 2020-02-27 Five Prime Therapeutics Inc Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
JP7573365B2 (ja) * 2016-08-12 2024-10-25 メルク パテント ゲーエムベーハー 癌の併用療法

Also Published As

Publication number Publication date
AU2019271065A1 (en) 2020-11-05
JP2021523096A (ja) 2021-09-02
EP3813868A4 (en) 2022-03-02
BR112020021082A2 (pt) 2021-02-17
US20210061899A1 (en) 2021-03-04
KR20210009339A (ko) 2021-01-26
CA3096844A1 (en) 2019-11-21
WO2019222252A1 (en) 2019-11-21
TW202003577A (zh) 2020-01-16
SG11202011148VA (en) 2020-12-30
EP3813868A1 (en) 2021-05-05
CN112118858A (zh) 2020-12-22

Similar Documents

Publication Publication Date Title
MY189536A (en) Subcutaneous her2 antibody formulations
MX2022010270A (es) Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion.
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
MX2016010082A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1) y un inhibidor del receptor del factor de crecimiento endotelial vascular (vegfr) para tratar cancer.
PH12016502354A1 (en) Pharmaceutical composition
EA201790352A1 (ru) Терапевтическое лечение на основе анаморелина
BR112018075660A2 (pt) métodos de tratamento de câncer de pâncreas
MX2016013025A (es) Focalizacion de cancer de mama her2+ resistente a trastuzumab con una nanoparticula dirigida de her3.
MX2017002364A (es) Terapia de combinacion para tratamiento de cancer.
IL281439A (en) Combined treatment for blood cancer
MX2020001727A (es) Terapia de combinacion.
EP4037761C0 (en) DEVICE FOR THE RADIOTHERAPY TREATMENT OF CANCER PATIENTS
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
IL281920A (en) Methods for the treatment of peripheral T-cell lymphoma using anti-CD30 antibody drug conjugate therapy
ZA202204423B (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
JOP20200124A1 (ar) طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
WO2019043649A3 (en) ANGIO -3 FOR THE TREATMENT OF RETINAL ANGIOGENIC DISEASES
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
BR112016023011A2 (pt) tratamento de câncer gástrico
MX2021007402A (es) Metodos para la toma de imagenes y el tratamiento de tumores positivos para el receptor de somatostatina.
MX2019003751A (es) Proteina terapeutica.
SG11202011148VA (en) Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naive subjects
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2020014166A (es) Regímenes de dosis para la inhibición dirigida del factor de crecimiento transformante beta (tgf-b) para usarse en el tratamiento de cáncer del tracto biliar.